BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PMX-30063: Phase I data

A double-blind, U.S. Phase I trial in 20 healthy volunteers showed that high-dose IV PMX-30063 was safe when administered for >5 days, with paraesthesia of the lips, face and fingers reported as the most common side effects....

Read the full 162 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >